BioKangtai(SZ:300601)2022-11-21 15:38Financial Performance - In the first three quarters of 2021, the company achieved operating revenue of 2.377 billion yuan, a year-on-year increase of 67.37% [2] - The net profit attributable to shareholders was 1.036 billion yuan, reflecting a year-on-year growth of 139.13% [2] Product Development - The company’s self-developed inactivated COVID-19 vaccine received emergency use approval in May 2021 and has begun large-scale sales [2] - The 13-valent pneumococcal polysaccharide conjugate vaccine, a global first, obtained drug registration certification in September 2021 and is now entering the market [3] - The freeze-dried human rabies vaccine (human diploid cells) has received acceptance for production registration application [3] Research and Innovation - The company is focusing on vaccine industry innovation, with ongoing development of multiple vaccine projects, including the freeze-dried varicella live vaccine and Sabin strain inactivated polio vaccine [4] - The company has established various research platforms for viral, bacterial, and genetic engineering vaccines, and is exploring new technologies, including mRNA [6] Market Strategy - The company is implementing a "bring in" and "go out" strategy to enhance its R&D capabilities and expand international market cooperation [5] - The sales team has over 1,000 members, and the company plans to expand this team as more products are launched [6] Future Outlook - The company aims to become a globally recognized supplier of biological vaccines, with a rich product pipeline expected to support rapid growth [5]